

**FOR IMMEDIATE RELEASE**

Genospectra, Inc  
6519 Dumbarton Circle  
Fremont, CA 94555  
Tel 888 317 2626  
Fax 510 818 2610  
[www.genospectra.com](http://www.genospectra.com)

**Contact:**

Melanie Mahtani, Ph.D.  
V.P., Business Development  
(510) 818-2689  
[mmahatani@genospectra.com](mailto:mmahatani@genospectra.com)

**GENOSPECTRA SIGNS EXCLUSIVE LICENSE AND MULTIYEAR COLLABORATION  
AGREEMENT WITH CNRS**

***To develop and commercialize a novel panel of peptide-based delivery reagents***

**Fremont, Calif., 19 July, 2005** --- Genospectra, Inc., developer of innovative products and technologies for parallel quantitative biology (PQB), and the exclusive provider of QuantiGene<sup>®</sup> and QuantiGene<sup>®</sup> Plex quantitative gene expression profiling technology, today announced an international agreement to develop a proprietary panel of optimized delivery reagents with CNRS, France.

The relationship provides Genospectra with a worldwide, exclusive license to the novel "MPG" technology developed by Drs. Frederic Heitz, May Morris, and Gilles Divita at "Centre de Recherches en Biochimie Macromoleculaire" at the CNRS in Montpellier-France. In addition, it establishes a joint research collaboration to develop a panel of delivery reagents optimized to transfer a wide variety of molecular cargoes into live cells. Under the terms of the agreement, Genospectra also retains exclusive, worldwide rights to the technology, and to market and sell products developed during the collaboration.

The agreement extends a two-year relationship between Genospectra and Dr. Divita of CNRS. An expert in molecular biophysics, Dr. Divita has used his research into the principles of mammalian viral infectiveness to develop a peptide-based nanoparticle system capable of efficient biomolecule delivery. Modifications to the peptide system enable specific cargoes -- such as proteins, peptides, plasmids, nucleic acids or other molecules -- to be selectively shuttled into live cells.

"We are very pleased that Genospectra recently launched the first product in its *Express Delivery* reagent line based on our MPG technology. This product, *Express-si Delivery*, is ideal for transferring siRNA into primary cells and difficult-to-transfect cells", said Dr. Divita. "Our MPG technology uniquely leverages the natural systems of the cell for biomolecule transfer, thereby solving the critical problems of cellular toxicity and endosomal capture that are associated with the common lipid-based delivery reagents."

Dr. Frank Witney, CEO of Genospectra added, “The *Express Delivery* product line is both a landmark area for Genospectra and a important product line for our PQB strategy in cell-based assays. In fact, the whole field of cellular assays and biosensors is in urgent need of technologies to safely and effectively bring molecular cargoes into difficult-to-transfect cells, including primary cells. It’s clear that we can significantly impact the understanding of molecular cell biology and pathway analysis with *Express Delivery* and other innovative technologies in our biosensor program to deliver, modulate, and quantify critical molecular reactions in live cells.”

### **About Genospectra**

Genospectra, Inc. is a privately-held life science company developing technologies and products for parallel quantitative biology (PQB™) for dynamic measurements of cellular biology. Genospectra’s PQB initiative is focused on creating novel cell-based assays and tools that enable multiplex measurements of molecular events, such as intracellular pathway analysis, in a quantitative and scalable manner. Genospectra has developed thousands of assays for the QuantiGene® Reagent System, which is powered by the proprietary branched-DNA technology for gene expression analysis in cell-based assays. This novel technology enables accurate and precise quantitation of RNA levels without RNA purification for biomarker analysis, RNA interference, microarray validation and predictive toxicology. The company's products are targeted to research cellular pathways, to dissect molecular models of human disease, and to discover the next generation of medicines. Genospectra is based in Fremont, California. For additional information, please visit the company’s website at [www.genospectra.com](http://www.genospectra.com).

### **About CNRS**

The French National Center for Scientific Research (CNRS) is a publicly-funded research organization that defines its mission as producing knowledge and making it available to society. CNRS has 26,000 employees (among which 11,600 researchers and 14,400 engineers and technical and administrative staff). Its budget amounts to 2.214 billion euros for the year 2004. The 1,260 CNRS service and research units are spread throughout the country and cover all fields of research.